[ Back to EurekAlert! ] Public release date: 15-Jan-2010
[ | E-mail Share Share ]

Contact: Marjorie Musick
mmusick@gmu.edu
703-993-8781
George Mason University

Novel personalized medicine trial launched for metastatic colorectal cancer

FAIRFAX, Va. -- Imagine if treatments for disease could be based not on a patient's diagnosis but instead on the characteristics of their tissue. By identifying and decoding the cryptic messages hidden deep inside the human proteome, scientists and physicians who study personalized medicine are seeking more effective treatments and disease management for patients.

Lance Liotta, MD, and Emanuel Petricoin, III, professors of life sciences and co-directors of George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM), are pioneers in the field of patient-tailored research and personalized medicine. The two are studying biomarkers (or indicators of disease in tissue and bodily fluids) related to cancer, heart disease, liver disease and obesity.

They recently launched a unique clinical trial in partnership with oncologists and co-principal investigators Kirstin Edmiston, MD, medical director of cancer services at Inova Health System, and Alexander I. Spira, MD, director of Fairfax Northern Virginia Hematology Oncology Research Program, to treat patients with late-stage colorectal cancer, a fatal cancer that starts in either the colon or the rectum.

The three-year trial will accommodate up to 50 men and women who have late-stage colorectal cancer that has spread to the liver. Striking more than 150,000 men and women each year in the United States, colorectal cancer is the nation's third most commonly diagnosed cancer and third leading cause of cancer death according to the American Cancer Society.

"Traditionally, all colon cancers have been lumped together and given similar treatments. The novelty about this is that we can, in a very minimally invasive way, start to treat the metastatic tumor based on its unique protein makeup. If we're going to be successful in treating the metastatic disease, which is what kills people, then we need to focus on using therapies targeted towards the individuality of a patient's disease state. This clinical trial is the first step toward doing that," says Edmiston.

Trial participants will be treated with standard metastatic colon cancer therapy and will test the addition of Gleevec, a medicine that is typically prescribed for certain forms of leukemia and gastrointestinal tumors. Gleevec targets disease pathways in tumor cells that previous CAPMM research revealed were among those found in typically fatal liver metastasis in colorectal cancer patients.

Because the primary tumors in the colon are removed in most colorectal cancer patients as soon as they are diagnosed, this study will focus on treating the often fatal secondary tumors or metastatic lesions that appear when the disease spreads to the liver, causing death through destruction of that organ.

Using a new drug target mapping technology called "reverse phase protein microarray" that was developed by CAPMM's scientists, the researchers will sample these lesions and create a unique molecular profile or "fingerprint" that shows which protein pathways or drug targets are activated in the lesion. This process will allow the researchers to determine whether specific drugs such as Gleevec might be an effective treatment for this particular patient before it is even administered.

By monitoring the drug target activity in trial participants' tumors and basing their treatment on those characteristics, the researchers are hopeful that this clinical trial will lead to more effective and individualized treatment for patients who suffer from this devastating disease.

"The exciting aspect of this trial is that an established drug is being considered for a new indication, and that's one of the promises of personalized therapy--that a patient's molecular portrait would be considered as the rationale for choice of therapy rather than based on the site or the kind of cancer alone," says Petricoin. "Until now, the most cutting edge clinical trials utilize genomic profiling of the tumor to select patients. This is the first trial that uses a direct proteomic approach that maps the drug target activation networks that are in use in each patient's tumor--just technologically being able to do this in a real clinical trial is a first."

###

Patients who are interested in participating should contact Stacey Banks, Inova's clinical research coordinator at 703-776-3565.

Financial support for the study is being provided by Novartis, which developed and manufactures Gleevec.

About Inova Health System

Inova Health System is a not-for-profit healthcare system based in Northern Virginia that consists of hospitals and other health services, including emergency- and urgent-care centers, home care, nursing homes, mental health and blood donor services, and wellness classes. Governed by a voluntary board of community members, Inova's mission is to improve the health of the diverse community it serves through excellence in patient care, education and research. Inova provides a healthy environment for its patients, families, visitors, staff and physicians by prohibiting tobacco use on its campuses.

About Fairfax Northern Virginia Hematology Oncology

Fairfax Northern Virginia Hematology Oncology (FNVHO) is northern Virginia's premier oncology and hematology practice of board certified physicians. The practice has 33 physician experts on cancer, blood disorders and stem cell transplantation in seven locations across northern Virginia. Comprehensive practice services include collaborative nursing, financial counseling and access to cutting-edge clinical trials through affiliations with US Oncology, the National Cancer Institute and many other cooperative groups. For more information, visit www.fnvho.com.

About George Mason University

Named the #1 national university to watch in the 2009 rankings of U.S. News & World Report, George Mason University is an innovative, entrepreneurial institution with global distinction in a range of academic fields. Located in Northern Virginia near Washington, D.C., Mason provides students access to diverse cultural experiences and the most sought-after internships and employers in the country. Mason offers strong undergraduate and graduate degree programs in engineering and information technology, organizational psychology, health care and visual and performing arts. With Mason professors conducting groundbreaking research in areas such as climate change, public policy and the biosciences, George Mason University is a leading example of the modern, public university.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.